Supplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma

Supplementary Table 1. Gene expression changes in 8505C after vemurafenib treatment.Supplementary Table 2. Gene expression changes in WRO after vemurafenib treatment.Supplementary Table 3. Gene expression changes in 8505C -Vem-Res 1 relative to parental 8505C.Supplementary Table 4. Gene expression changes in WRO -Vem-Res 6 relative to parental WRO.Supplementary Table 5. Clinical features of thyroid tumors used in Fig. 5.

补充表 1. 8505C 细胞在 vemurafenib 治疗后基因表达的变化。补充表 2. WRO 细胞在 vemurafenib 治疗后基因表达的变化。补充表 3. 与亲本 8505C 相比，8505C -Vem-Res 1 的基因表达变化。补充表 4. 与亲本 WRO 相比，WRO -Vem-Res 6 的基因表达变化。补充表 5. 用于图 5 的甲状腺肿瘤的临床特征。